On August 16, 2016, Lawrence Fong, M.D., professor and leader of the Cancer Immunotherapy Program at the University of California, San Francisco / Helen Diller Family Comprehensive Cancer Center, discussed current immunotherapy options for patients with prostate cancer.
Dr. Fong focuses on how the immune system interacts with cancer, as well as the development of tumor immunotherapies in both mouse models and in patients. Fong has been involved in the preclinical and clinical studies with sipuleucel-T (Provenge) and ipilimumab (Yervoy), which are now FDA approved for prostate cancer and melanoma, respectively. Dr. Fong obtained his M.D. at Stanford University, completed internal medicine training at University of Washington, and an oncology fellowship at Stanford.
This webinar is part of the Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This series is presented by Genentech and LabAnswer and its employees, with generous support from Abbvie, Celldex Therapeutics, NewLink Genetics, and Regeneron. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.